S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Sell every Stock except ONE (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What’s At Stake In April is Shocking (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Sell every Stock except ONE (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What’s At Stake In April is Shocking (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Sell every Stock except ONE (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What’s At Stake In April is Shocking (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Sell every Stock except ONE (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What’s At Stake In April is Shocking (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
NASDAQ:UBX

Unity Biotechnology - UBX Stock Forecast, Price & News

$1.63
-0.07 (-4.12%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.63
$1.73
50-Day Range
$1.63
$5.51
52-Week Range
$1.63
$18.50
Volume
513,696 shs
Average Volume
396,170 shs
Market Capitalization
$23.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Unity Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
298.8% Upside
$6.50 Price Target
Short Interest
Bearish
8.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
-0.04mentions of Unity Biotechnology in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$13,933 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.82) to ($6.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

695th out of 1,004 stocks

Pharmaceutical Preparations Industry

345th out of 489 stocks


UBX stock logo

About Unity Biotechnology (NASDAQ:UBX) Stock

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $5.00
Expert Ratings for Unity Biotechnology
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
Unity Biotechnology: One Last Chance With UBX1325
Wedbush Reaffirms Their Buy Rating on Unity Biotechnology (UBX)
See More Headlines
Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Company Calendar

Last Earnings
11/10/2021
Today
3/31/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:UBX
Fax
N/A
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+298.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-59,930,000.00
Pretax Margin
-25,392.80%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$4.71 per share

Miscellaneous

Free Float
13,823,000
Market Cap
$23.37 million
Optionable
Not Optionable
Beta
0.79

Key Executives

  • Anirvan Ghosh
    Chief Executive Officer & Director
  • Nathan Guz
    Vice President-Operations
  • Lynne Sullivan
    Chief Financial Officer
  • Jamie Dananberg
    Chief Medical Officer
  • Alexander Nguyen
    Secretary & General Counsel













UBX Stock - Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UBX shares.
View UBX analyst ratings
or view top-rated stocks.

What is Unity Biotechnology's stock price forecast for 2023?

5 Wall Street analysts have issued 12-month target prices for Unity Biotechnology's shares. Their UBX share price forecasts range from $5.00 to $10.00. On average, they expect the company's share price to reach $6.50 in the next year. This suggests a possible upside of 286.9% from the stock's current price.
View analysts price targets for UBX
or view top-rated stocks among Wall Street analysts.

How have UBX shares performed in 2023?

Unity Biotechnology's stock was trading at $2.74 at the start of the year. Since then, UBX shares have decreased by 38.7% and is now trading at $1.68.
View the best growth stocks for 2023 here
.

When is Unity Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our UBX earnings forecast
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) issued its earnings results on Wednesday, November, 10th. The company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($3.60) by $0.60.

When did Unity Biotechnology's stock split?

Shares of Unity Biotechnology reverse split on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Alyeska Investment Group L.P. (4.92%), 683 Capital Management LLC (1.69%), Mayo Clinic (1.11%), Mayo Clinic (1.11%), Renaissance Technologies LLC (0.64%) and Geode Capital Management LLC (0.64%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg and Nathaniel E David.
View institutional ownership trends
.

How do I buy shares of Unity Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $1.68.

How much money does Unity Biotechnology make?

Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $24.09 million and generates $240,000.00 in revenue each year. The company earns $-59,930,000.00 in net income (profit) each year or ($7.06) on an earnings per share basis.

How can I contact Unity Biotechnology?

The official website for the company is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192 or via email at ir@unitybiotechnology.com.

This page (NASDAQ:UBX) was last updated on 4/1/2023 by MarketBeat.com Staff